MEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)
|
|
|
- Coral Rodgers
- 5 years ago
- Views:
Transcription
1 NOVEMBER 2018 MEDICINES CATALOG GLOBAL DRUG FACILITY (GDF) Ensuring an uninterrupted supply of quality-assured, affordable tuberculosis (TB) medicines and diagnostics to the world. stoptb.org/gdf
2 Stop TB Partnership Global Drug Facility Global Health Campus Chemin du Pommier Le Grand-Saconnex Geneva, Switzerland
3 GLOBAL DRUG FACILITY MEDICINES CATALOG NOVEMBER 2018 GDF is the largest global provider of quality-assured tuberculosis (TB) medicines, diagnostics, and laboratory supplies to the public sector. Since 2001, GDF has facilitated access to high-quality TB care in over 130 countries, providing treatments to over 30 million people with TB and procuring and delivering more than $200 million worth of diagnostic equipment. As a unit of the Stop TB Partnership, GDF provides a range of quality-assured medicines and medical supplies to treat all forms of TB in adults, adolescents and children. This catalog is categorized by products used to treat adults and adolescents as well as children. Each section is subdivided into single medicines and fixed-dose combinations, in alphabetical order by the description. Each product is marked for its intended use, as recommended by WHO, i.e. to treat drug-sensitive TB, drug-resistant TB and/or latent TB infections. To place an order for any medicine or medical supply, please follow the step-by-step guide available on the GDF website. All prices in this catalogue are listed as ex-works (EXW) prices. stoptb.org/gdf
4 TABLE OF CONTENTS ADULT & ADOLESCENT FORMULATIONS SINGLE MEDICINES FIXED-DOSE COMBINATIONS CHILD-FRIENDLY FORMULATIONS SINGLE MEDICINES FIXED-DOSE COMBINATIONS MEDICAL SUPPLIES 09 2 MEDICINES CATALOG AUGUST 2018
5 ADULT & ADOLESCENT FORMULATIONS These formulations are indicated for the treatment of all kinds of TB in adults and adolescents. SINGLE MEDICINES Am-500-(A)-10 Amx/Clv-250/ 125-(B)-14 DESCRIPTION (MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) Amikacin, 500 mg/2 ml, Solution for injection, Ampoule(s) acid, 250 mg/125 mg, Film (USD) * ** ADULT & ADOLESCENT FORMULATIONS Amx/Clv-250/ 125-(B)-20 Amx/Clv-500/ 125-(B)-15 Amx/Clv-500/ 125-(B)-100 Amx/Clv-875/ 125-(B)-12 Amx/Clv-875/ 125-(B)-100 acid, 250 mg/125 mg, Film acid, 500 mg/125 mg, Film acid, 500 mg/125 mg, Film acid, 875 mg/125 mg, Film acid, 875 mg/125 mg, Film ** ** ** ** ** Bdq-100-(L)-188 Bedaquiline, 100 mg, Uncoated tablet(s), HDPE container(s) 188 Please contact GDF 4 Cm-1-(V)-1 Capreomycin, 1 g, Powder, for injection, Vial(s) Cm-1-(V)-10 Capreomycin, 1 g, Powder,for injection, Vial(s) (please contact GDF for availability) (please contact GDF for availability) Cfz-100-(L)-100 Clofazimine, 100 mg, Capsule(s), HDPE jar(s) * Price ranges shown are the lowest and highest available. Actual prices within the indicated range will be based on order volume, requested delivery time and country regulatory requirements. For budgetary purposes, countries are encouraged to use the highest price available. ** To be used with imipenem/cilastatin or meropenem only GLOBAL DRUG FACILITY 3
6 ADULT & ADOLESCENT FORMULATIONS SINGLE MEDICINES Cs-250-(B)-100 Dlm-50-(B)-672 E-400-(B)-672 Eto-250-(B)-100 Imp/Cls-500/ 500-(V)-10 H-300-(B)-672 DESCRIPTION (MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) Cycloserine, 250 mg, Capsule(s), Delamanid, 50 mg, Film Ethambutol, 400 mg, Film Ethionamide, 250 mg, Film Imipenem/Cilastatin, 500 mg/500 mg, Powder, for injection, Vial(s) Isoniazid, 300 mg, Un (USD) , Km-1-(V)-50 Km-0.5-(V)-50 Km-1-(A)-10 Lfx-250-(B)-100 Lfx-500-(B)-100 Lfx-750-(B)-100 Lnz-600-(B)-10 Lnz-600-(B)-100 Mrp-1-(V)-1 Mfx-400-(B)- 100 Kanamycin, 1 g, Powder, for injection, Vial(s) Kanamycin, 0.5 g, Powder, for injection, Vial(s) Kanamycin, 1 g/4 ml, Powder, for injection, Ampoule(s) Levofloxacin, 250 mg, Film Levofloxacin, 500 mg, Film coated tablet(s), Levofloxacin, 750 mg, Film Linezolid, 600 mg, Film Linezolid, 600 mg, Film Meropenem, 1 g, Powder, for injection, Vial(s) Moxifloxacin, 400 mg, Film (please contact GDF for availability) (please contact GDF for availability) (please contact GDF for availability) GLOBAL DRUG FACILITY
7 SINGLE MEDICINES PAS-(H)-4-(S)- 30 PAS-(Na)-4-(S)- 25 PAS-(Na)-4-(S)- 30 Pto-250-(B)-100 Z-400-(B)-672 DESCRIPTION (MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) PAS Acid, 4 g, Granule(s), Sachet PAS Sodium Salt, 4 g, Granule(s), Sachet PAS Sodium Salt, 4 g, Granule(s), Sachet Prothionamide, 250 mg, Film coated tablet(s), Pyrazinamide, 400 mg, Uncoated tablet(s), (USD) ADULT & ADOLESCENT FORMULATIONS Z-500-(B)-120 Z-500-(B)-672 Pyr(B6)-50-(B)- 50 Pyr(B6)-100-(L)- 250 Rbt-150-(L) -100 R-150-(B)-100 R-300-(B)-100 Rpt-150-(B)-24 S-1-(V)-10 S-1-(V)-100 Trd- 250-(B)-50 Pyrazinamide, 500 mg, Film coated tablet(s), Pyrazinamide, 500 mg, Uncoated tablet(s), Pyridoxine, 50 mg, Film Pyridoxine, 100 mg, Uncoated tablet(s), HDPE jar(s) Rifabutin, 150 mg, Capsule(s), HDPE jar(s) Rifampicin, 150 mg, Film Rifampicin, 300 mg, Film Rifapentine, 150 mg, Film Streptomycin, 1 g, Powder, for injection, Vial(s) Streptomycin, 1 g, Powder, for injection, Vial(s) Terizidone, 250 mg, Capsule(s), GLOBAL DRUG FACILITY 5
8 ADULT & ADOLESCENT FORMULATIONS FIXED-DOSE COMBINATIONS PK-Cat I & III-A HPST-Q-TIB- (L)-30 2-FDC/RH-150/ 75-(B)-336 DESCRIPTION MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) Cat I & III Kit A, Film Isoniazid/ Pyridoxine hydrochl/ Sulfamethoxazole/ Trimethoprim, 300 mg/ 25 mg/800 mg/160 mg, Uncoated tablet(s), HDPE container(s) Rifampicin/Isoniazid, 150 mg/75 mg, Film (USD) FDC/RH-150/ 75-(B) FDC/ RHE-150/75/ 275-(B) FDC/ RHZE-150/ 75/400/ 275-(B) FDC/ RHZE-150/ 75/400/ 275-(B)-672 Rifampicin/Isoniazid, 150 mg/75 mg, Film Rifampicin/Isoniazid/ Ethambutol, 150 mg/75 mg/275 mg, Film coated tablet(s), Rifampicin/Isoniazid/ Pyrazinamide/ Ethambutol, 150 mg/75 mg/400 mg/ 275 mg, Film coated tablet(s), Rifampicin/Isoniazid/ Pyrazinamide/ Ethambutol, 150 mg/75 mg/400 mg/ 275 mg, Film coated tablet(s), GLOBAL DRUG FACILITY
9 CHILD-FRIENDLY FORMULATIONS These formulations make it easier for care-givers to give the correct doses and are simpler to administer to children. SINGLE MEDICINES Amx/Clv-125- (BTL)-1 DESCRIPTION (MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) acid, powder, for oral suspension, HDPE container(s) (USD) * CHILD-FRIENDLY FORMULATIONS Cs-125-(B)-100 E-100-(B-DT)- 100 E-100-(B)-100 Eto-125-(B-DT)- 100 Eto-125-(B)-100 H-100-(B)-100 H-100-(B-DT)-100 Lfx-100-(B-DT)- 100 Mfx-100- (B-DT)-100 Z-150-(B-DT)- 100 Cycloserine, 125 mg, Capsule(s), Ethambutol, 100 mg, Dispersible tablet(s), Ethambutol, 100 mg, Film Ethionamide, 125 mg, Dispersible tablet(s), Ethionamide, 125 mg, Film Isoniazid, 100 mg, Uncoated tablet(s), Isoniazid, 100 mg, Dispersible tablet(s), Levofloxacin, 100 mg, Dispersible tablet(s), Moxifloxacin, 100 mg, Dispersible tablet(s), Pyrazinamide, 150 mg, Dispersible tablet(s), Strip(s) * To be used with imipenem/cilastatin or meropenem only. GLOBAL DRUG FACILITY 7
10 CHILD-FRIENDLY FORMULATIONS FIXED-DOSE COMBINATIONS 2-FDC/RH-75/ 50-(B)-84 3-FDC/ RHZ-75/50/ 150-(B)-84 DESCRIPTION (MEDICINE, STRENGTH, FORMULA- TION, PACKAGING) Rifampicin/Isoniazid, 75 mg/50 mg, Dispersible tablet(s), Strip(s) Rifampicin/Isoniazid/ Pyrazinamide, 75 mg/50 mg/150 mg, Dispersible tablet(s), (USD) GLOBAL DRUG FACILITY
11 MEDICAL SUPPLIES GDF facilitates access to medical supplies used in treating TB. S&N - 5 ml/21 G (RUP/SIP) DESCRIPTION (, PACKAGING) (USD) AD Syringes (RUP/SIP) MEDICAL SUPPLIES S&N - 5 ml/23 G (RUP/SIP) S&N - 5 ml/22 G (RUP/SIP) Safety box for used S&N - 5L AD Syringes (RUP/SIP) AD Syringes (RUP/SIP) Safety Box for used S&N S&N-5/22Gx1.5 and Safety Box, 5lt S&N-5/21Gx1.5 and Safety Box, 5lt S&N-5/23Gx1 and Safety Box, 5lt WFI-5-(V)-100 WFI-5-(V)-50 Syringe & needle (auto-disabling) Syringe & needle (auto-disabling) Syringe & needle (auto-disabling) Water for injections, Solution for injection, Vial(s) Water for Injections, Solution for injection, Vial(s) GLOBAL DRUG FACILITY 9
12 Stop TB Partnership Global Drug Facility Global Health Campus Chemin du Pommier Le Grand-Saconnex Geneva, Switzerland
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
Invitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
HA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building
Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention
REPORT ON GREEN LIGHT COMMITTEE MONITORING MISSION INDONESIA. January Michael Rich, M.D., M.P.H. Date of mission: January 2017
REPORT ON GREEN LIGHT COMMITTEE MONITORING MISSION INDONESIA Michael Rich, M.D., M.P.H. Date of mission: 15-27 January 2017 January 2017 Acknowledgments The monitoring team would like to express gratitude
Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India
AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first
Procurement update: StopTB Partnership - Global Drug Facility (GDF)
Procurement update: StopTB Partnership - Global Drug Facility (GDF) Magali BABALEY Strategic Procurement and Business Intelligence Manager Stop TB Partnership, Global Drug Facility (GDF) team joint UNICEF-UNFPA-WHO
The Evaluation of Effectiveness and Safety of Novel Shorter. Treatment Regimens for Multidrug-Resistant Tuberculosis
The Evaluation of Effectiveness and Safety of Novel Shorter Treatment Regimens for Multidrug-Resistant Tuberculosis Operational Research Protocol Template May 2018 A publication of the Global Drug-resistant
DR-TB Patient Treatment Log Book
REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016 DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred
Terapia delle forme multi-resistenti
Ferrara, 31 Maggio 2018 Terapia delle forme multi-resistenti Dr. Marina Tadolini U.O. Malattie Infettive Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Outline
MDR-TB: Medicine quality and rational use
MDR-TB: Medicine quality and rational use Hans V. Hogerzeil, MD, PhD, FRCP Edin Director, Essential Medicines and Pharmaceutical Policies WHO, Geneva 1 Can we rely on essential medicines against TB? (1)
New TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis.
Chapter 5 Treatment. 5.1 First-Line Antituberculous Treatment
Chapter 5 Treatment Abstract In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3 Notice This guide is a draft version designed to give guidance to the endtb Project site on the use of new TB
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3 Notice This guide is designed to give guidance to the endtb Project site on the use of new TB drugs bedaquiline
Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic A. Kadyrov, PhD in Medicine Director
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
University of Groningen
University of Groningen Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis Maryandyshev, Andrey; Pontali, Emanuele; Tiberi, Simon; Akkerman,
WHO treatment guidelines for isoniazid-resistant tuberculosis
Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World
Multidrug-Resistant Tuberculosis
Pocket Book Multidrug-Resistant Tuberculosis National Clinical Management Training Content 1. Abbreviations 3. Diagnosis of Tuberculosis 4. DS-TB Treatment Monitoring 5. IPT Screening Algorithm 6. ART
Overcoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
Update on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.2
endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.2 Notice This guide is a draft version designed to give guidance to the endtb Project site on the use of new TB
Green Light Committee for the WHO European Region
Green Light Committee for the WHO European Region Country support mission report Ukraine 17 21 September 2018 Country: Ukraine Dates: 17 21 September 2018 Consultants: Content editors: Language editor:
TB Local epidemiology and clinical challenges. Dr John Black Livingstone Hospital
TB Local epidemiology and clinical challenges Dr John Black Livingstone Hospital 2015 NHLS de- duplicated data DISTRICT/SUB- DISTRICT TOTAL PTB CASES No. TESTED NEGATIVE TOTAL TESTED POSITIVITY
OUT OF TIME: ACCESS TO TREATMENT FOR DR- TB
MSF Briefing Document DECEMBER 2015 OUT OF TIME: ACCESS TO TREATMENT FOR DR- TB An update on the latest developments in DR- TB medicines In 2014, 1.5 million people died from tuberculosis (TB), displacing
Updates on the global TB Global TB burden Policy response Treatment approaches
Ernesto Updates on the global TB Global TB burden Policy response Treatment approaches Ernesto Jaramillo WHO Global TB Programmme World Health Organization, Geneva, Tuberculosis is the leading infectious
4-6 Km-Mfx-Pto-Cfz-Z-H high-dose -E / 5 Mfx-Cfz-Z-E
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions Version: 20 December 2016 These FAQs are to be read
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
APSR RESPIRATORY UPDATES
Volume 11 Issue 1 Newsletter Date: January 2019 APSR EDUCATION PUBLICATION Inside this issue: Updates on Treatment in Drug Resistant Tuberculosis World TB Day 2018: the challenge of drug resistant tuberculosis
ACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
PREPARATION OF DRUGS FOR DST TESTING
PREPARATION OF DRUGS FOR DST TESTING Rev 1 Pag. 1 di 7 Destinatari: Coordinatore, Tecnici del Settore Micobatteri - EBP CONTENT 1. SCOPE 2. APPLICATION 3. DEFINITIONS AND ABBREVIATIONS 4. RESPONSIBILITIES
Using delamanid in MDR-TB Francis Varaine MSF
Using delamanid in MDR-TB Francis Varaine MSF Symposium on new treatment and approaches to Tuberculosis Yerevan TB February 2015 A new anti-tb drug Nitro-dihydro-imidazo-oxazole derivative Mechanism of
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
UN HIGH-LEVEL MEETING ON TB KEY TARGETS & COMMITMENTS FOR 2022
UN HIGH-LEVEL MEETING ON TB KEY TARGETS & COMMITMENTS FOR 2022 UNHLM ON TB KEY TARGETS FOR 2022 WE, HEADS OF STATE AND GOVERNMENT AND REPRESENTATIVES OF STATES AND GOVERNMENTS ASSEMBLED AT THE UNITED NATIONS
Marcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
Bedaquiline and delamanid Experience of use in children. Bobojon Sharipov Deputy Director of the Republican Tuberculosis Control Centre
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
Current Status in the Development of the New Anti-Tuberculosis Drugs
National Scientific Meeting TB UPDATE IX 2017 WORKSHOP AND SYMPOSIUM Novel Management to End TB Hotel Bumi Surabaya 29-30 April 2017 Current Status in the Development of the New Anti-Tuberculosis Drugs
TRAITEMENT DE MYCOBACTERIUM TUBERCULOSIS MULTIRÉSISTANT
TRAITEMENT DE MYCOBACTERIUM TUBERCULOSIS MULTIRÉSISTANT LORENZO GUGLIELMETTI RICAI, 18 DÉCEMBRE 2017 CNR des Mycobactéries OUTLINE Introduction New regimens and new drugs New drugs in France Future perspectives
Our experience on other diseases
Global supply chain for MDR TB drugs Our experience on other diseases Dr Robert Sebbag 31 st July 2012 ACCESS TO MEDICINES 1 Second-line drugs for MDR TB Definition: resistance to (at least) R and H, the
MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
New Frontiers: Innovation and Access
8 th Regional TB Symposium - Tashkent, Uzbekistan New Frontiers: Innovation and Access New Guidelines: An Opportunity for National Programmes and Patients: Evidence for new WHO recommendations on MDR-TB
The shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
Tuberculosis Medicines
2013 Tuberculosis Medicines Technology and Market Landscape SEPTEMBER 2013 2013 Tuberculosis Medicines Technology and Market Landscape UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211
Pediatric TB Intensive San Antonio, Texas October 14, 2013
Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following
Pharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
PAEDIATRIC TB TRIAL UPDATE
PAEDIATRIC TB TRIAL UPDATE ANNEKE C. HESSELING PROFESSOR IN PAEDIATRICS AND CHILD HEALTH DIRECTOR: DESMOND TUTU TB CENTRE DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH STELLENBOSCH UNIVERSITY, SOUTH AFRICA
Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis
Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis WHO/CDS/TB/2018.6 World Health Organization 2018 Some rights reserved.
Managing Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
Iqbal Master Clinical Manager King Dinuzulu Hospital complex MDR TB UPDATE AWACC 2018
Iqbal Master Clinical Manager King Dinuzulu Hospital complex MDR TB UPDATE AWACC 2018 Challenges MDR faced & what was achieved The current program Key drugs The New Regimens Stats Limited facilities/ MDR
Management of Tuberculosis Training for Health Facility Staff
Management of Tuberculosis Training for Health Facility Staff SECOND EDITION F. Manage Drugs and Supplies for TB Management of Tuberculosis Training for Health Facility Staff Second Edition F MANAGE DRUGS
Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB
Frequently Asked Questions on the WHO Rapid Communication: key changes to the treatment of multidrug- and rifampicin-resistant TB Version: 1.0 Prepared by the WHO Task Force to support country transition
2nd DR-TB DRUGS UNDER THE MICROSCOPE
2nd DR-TB DRUGS UNDER THE MICROSCOPE Sources and prices for drug-resistant tuberculosis medicines 2nd Edition November 2012 www.msfaccess.org www.theunion.org The MSF Access Campaign In 1999, in the wake
Short Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
Development of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY 10005 USA 1 Outline What are the unmet needs in TB
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
Diagnosis and Management. of Tuberculosis
Chapter 6 Tuberculosis: New Laboratory Diagnostic Methods and Treatment Hongfei Duan 1 ; Zihui Li 2 ; Xiaojing Zheng 2 ; Zongde Zhang 2 ; Naihui Chu 1 1 Beijing Chest Hospital, Capital Medical University,
2. Name of the focal point in WHO submitting or supporting the application (where relevant)
Essential Medicines List (EML) 2015 Application for the inclusion of terizidone in the WHO Model List of Essential Medicines, as reserve second line drugs for the treatment of multidrug resistant tuberculosis
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
EDITORIAL TUBERCULOSIS Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases Jose A. Caminero 1,2, Alberto Piubello 2,3, Anna Scardigli 4 and 5
Access update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Access update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF EML Guidelines
Pharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
ENDING AIDS, TB AND MALARIA AS EPIDEMICS
ENDING AIDS, TB AND MALARIA AS EPIDEMICS A SMART INVESTMENT In 2000, AIDS, tuberculosis and malaria appeared to be unstoppable. In many countries, AIDS devastated an entire generation, leaving countless
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital
Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in
Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
World Health Organization 2010
WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines 4th ed. WHO/HTM/TB/2009.420 1.Antitubercular agents administration and dosage. 2.Tuberculosis, Pulmonary drug therapy.
MINISTRY OF HEALTH, MALAWI. GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF MANAGEMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS IN MALAWI
MINISTRY OF HEALTH, MALAWI. GOVERNMENT OF MALAWI GUIDELINES FOR THE PROGRAMMATIC MINISTRY OF HEALTH MANAGEMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS IN MALAWI GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT
What is the recommended shorter treatment regimen for MDR-TB?
DRTB STAT + TAG BRIEF Is shorter better? Is shorter better? Understanding the shorter regimen for treating drugresistant tuberculosis by Safiqa Khimani Edited by Vivian Cox, Mike Frick, Jennifer Furin,
Drug Discoveries & Therapeutics. 2015; 9(3): Multidrug resistant tuberculosis treatment in India
156 Review DOI: 10.5582/ddt.2015.01012 Multidrug resistant tuberculosis treatment in India Rajendra Prasad 1, *, Nikhil Gupta 2, Viswesvaran Balasubramanian 1, Abhijeet Singh 1 1 Department of Pulmonary
Anti Tuberculosis Medications
Anti Tuberculosis Medications Mary Ann Rodriguez, MD March 8, 2017 TB Nurse Case Management March 7 9, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Mary Ann Rodriguez, MD has the following disclosures
Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India
Revised National Tuberculosis Control Programme Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India March 2017 Central TB Division, Directorate General of Health Services, Ministry
Lessons to be learned from HIV, TB and Malaria
Lessons to be learned from HIV, TB and Malaria Informal Consultation of Member States and relevant partners on the global development and stewardship framework to combat antimicrobial resistance Stewardship
Companion handbook. to the WHO guidelines for the programmatic management of drug-resistant tuberculosis
Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis
Overview of Drug Resistant Mycobacterium tuberculosis
Int. J. Life. Sci. Scienti. Res. eissn: 2455-1716 Review Article Overview of Drug Resistant Mycobacterium tuberculosis 1 2 Anurag Rai *, Taiyaba khan 1 Tutor, Department of Microbiology, Prasad Institute
Biomolecular diagnostics, gene sequencing and whole genome sequencing. Rob Warren
Biomolecular diagnostics, gene sequencing and whole genome sequencing Rob Warren Classic molecular epidemiology IS6110 DNA fingerprinting (between 0 and 26 loci) Spoligotyping (1 locus) MIRU-VNTR (24 loci)
Update on Tuberculosis Botswana, March 2017
Update on Tuberculosis Botswana, March 2017 Zelalem Temesgen, MD FIDSA AAHIVS Professor of Medicine Executive Director, Mayo Clinic Center for Tuberculosis Director, HIV Program Regional Training and
Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
WSLH Testing and Surveillance Updates
WSLH Testing and Surveillance Updates Wisconsin Mycobacteriology Laboratory Network annual conference November 4, 2015, Madison, WI Updates Outline Collection and Transport Smear and Culture Nucleic Acid
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes
Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
RECENT ADVANCES OF TUBERCULOSIS MANAGEMENT. Qais Abdulmajeed Haddad Consultant ID & IC Security Forces Hospital Program Riyadh - Saudi Arabia
RECENT ADVANCES OF TUBERCULOSIS MANAGEMENT Qais Abdulmajeed Haddad Consultant ID & IC Security Forces Hospital Program Riyadh - Saudi Arabia RECENT ADVANCES OF TUBERCULOSIS MANAGEMENT History Epidemiology
FIND and NDWG symposium Panel Discussion. Martina Casenghi, NDWG Core Group
FIND and NDWG symposium Panel Discussion Martina Casenghi, NDWG Core Group 48 Union World Conference, Guadalajara October 11th 2017 Molecular tests for diagnosis of TB and drug resistance 2008 Dec 2010
Tuberculosis treatment
J Bras Pneumol. 2017;43(5):472-486 http://dx.doi.org/10.1590/s1806-37562016000000388 REVIEW ARTICLE Tuberculosis treatment Marcelo Fouad Rabahi 1,2, José Laerte Rodrigues da Silva Júnior 2, Anna Carolina
Certainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
Ministry of Health NATIONAL TUBERCULOSIS CONTROL PROGRAMME FORMULARY
Ministry of Health NATIONAL TUBERCULOSIS CONTROL PROGRAMME FORMULARY AUGUST 2015 Ministry of Health NATIONAL TUBERCULOSIS CONTROL PROGRAMME FORMULARY AUGUST 2015 This document was produced with support
Multidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
Medication Fact Sheets
5 Medication Fact Sheets 3rd edition contributors: GISELA F. SCHECTER, MD, MPH & CHARLES A. PELOQUIN, PharmD, FCCP Amikacin............... 100 Meropenem............ 130 Amoxicillin/clavulanate... 102 Moxifloxacin............
Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending
EDITORIAL TUBERCULOSIS Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending Max Salfinger 1 and Giovanni Battista Migliori 2 Affiliations: 1 Dept of Medicine, National
Omar Akramur Rab ISSN
Drug Resistant Tuberculosis... Page 01 Depression in the Elderly... Page 10 Drug Hypersensitivity Reactions... Page 13 SQUARE in International Business... Page 18 Product Profile-Anca... Page 19 Medical
Bedaquiline- and delamanidcontaining. achieve excellent interim treatment response without safety concerns. endtb interim analysis
Bedaquiline- and delamanidcontaining regimens achieve excellent interim treatment response without safety concerns endtb interim analysis July 2018 This preliminary report contains results as of 5 July
Management of Tuberculosis Training for Health Facility Staff. F: Manage Drugs and Supplies for TB. WORLD HEALTH ORGANIZATION Geneva
Management of Tuberculosis Training for Health Facility Staff F: Manage Drugs and Supplies for TB WORLD HEALTH ORGANIZATION Geneva WHO/CDS/TB/2003.314f Management of Tuberculosis Training for Health Facility
(AN ADDENDUM TO NTBLCP 2016 PMDT GUIDELINES 2 ND EDITION)
GUIDELINES ON THE USE OF THE SHORTER REGIMEN AND NEW DRUGS IN THE CLINICAL AND PROGRAMMATIC MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS AND CO-INFECTIONS OF NIGERIA. (AN ADDENDUM TO NTBLCP 2016 PMDT GUIDELINES
MINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 2017 A
MINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 1st August 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders
Application for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines
Application for addition of 3-FDC rifampicin 150/isoniazid 75/ethambutol 275 mg (RHE) to the WHO model list of essential medicines Geneva, 10 August 2006 Focal Point: Hugo Vrakking Global Drug Facility
Tuberculosis medications: adverse drug reactions
Tuberculosis medications: adverse drug reactions Rajesh M. Prabhu, M.D. Infectious Diseases Essentia Health, Duluth, MN July 25, 2017 2014 MFMER slide-1 No Finanial Disclosures Learning Objectives 1. Describe
Management of MDR TB in special situations. Dr Sarabjit Chadha The Union
Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
WHO/CDS/TB/ WHO/EDM/PAR/ Operational guide
WHO/CDS/TB/2002.308 - WHO/EDM/PAR/2002.6 Operational guide for national tuberculosis control programmes on the introduction and use of fixed-dose combination drugs WORLD HEALTH ORGANIZATION WHO/CDS/TB/2002.308
A FRAMEWORK FOR THE HARMONIZED MANAGEMENT OF TUBERCULOSIS IN THE MINING SECTOR. March, 2014
A FRAMEWORK FOR THE HARMONIZED MANAGEMENT OF TUBERCULOSIS IN THE MINING SECTOR March, 2014 TABLE OF CONTENTS TABLE OF CONTENTS...2 LIST OF ABBREVIATIONS...5 ACKNOWLEDGEMENTS...6 FOREWORD...7 PART 1: BACKGROUND...10